Urovant Sciences Initiates Phase 3 Clinical Program with Vibegron for Overactive Bladder in Men with Benign Prostatic Hyperplasia
IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Mar 27, 2019--Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company developing and commercializing innov…
